Hinojosa-Azaola A, Alcocer-Varela J

Language: Spanish
References: 36
Page: 477-486
PDF size: 219.24 Kb.

Text Extraction

No abstract.

REFERENCES

1. Strowig T, Henao-Mejia J, Elinav E, et al. Inflammasomes in health and disease. Nature 2012; 481: 278-86.

2. Khare S, Luc N, Dorfleutner A, et al. Inflammasones and their activation. Crit Rev Immunol 2010; 30: 463-87.

3. Lachmann HJ, Quartier P, So A, et al. The emerging role of Interleukin- 1 in Autoinflammatory Diseases. Arthritis Rheum 2011; 63: 314-24.

4. Touitou I. Autoinflammatory Diseases. Best Pract Res Clin Rheum 2008; 63: 811-29.

5. Davis BK, Wen H, Ting JP. The Inflammasome NLRs in Immunity, Inflamation, and Associated Diseases. Annu Rev Immunol 2011; 29: 707-35.

6. Ozkurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2011; 167: 382-90.

7. Mankan AK, Kubarenko A, Hornung V. Immunology in clinic review series; focus on autoinflammatory diseases: Inflammasomes: Mechanisms of activation. Clin Exp Immunol 2011; 167: 369-81.

8. Drenth J, van der Meer JWM. The Inflammasome -A Linebacker of Innate Defense. N Engl J Med 2006; 355: 730-32.

9. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: Update on monogenic autoinflammatory diseases: The role of Interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2011; 167: 391-404.

10. West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol 2011; 11: 389-402.

11. Iyer SS, et al. Necrotic cells trigger a sterile inflammatory response through the NLRP3 inflammasome. Proc Natl Acad Sci. ISA 2009; 106: 20388-93.

12. Kepp O, Galluzzi L, Kroemer G. Mitochondrial control of the NLRP3 inflammasome. Nat Immunol 2011; 12: 199-200.

13. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-59.

14. Simon A, van der Meer JWM. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007; 292: 86-98.

15. Padeh S. Periodic Fever Syndromes. Pediatr Clin N Am 2005; 52: 577-609.

16. Lachmann HJ, Hawkins PN. Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther 2009; 11: 212.

17. Masters SL, Simon A, Aksentijevich I, et al. Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease. Annu Rev Immunol 2009; 27: 621-68.

18. McDermott MF. A common pathway in periodic fever syndromes. TRENDS Immunol 2004; 25: 457-59.

19. Goldsmith DP. Periodic fever syndromes. Pediatr Rev 2009; 30: e34-e41.

20. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15: 61-69.

21. Drenth J, Van Der Meer JWM. Hereditary periodic fever. N Engl J Med 2001; 345: 1748-57.

22. Milhavet F, Cuisset L, Hoffman HM, et al. The Infeveres Autoinflamamtory Mutation Online Registry: Update with new genes and functions. Hum Mutat 2008; 29: 803-08.

23. Toplak N, Frenkel J, Ozen S, et al. An International registry in Autoinflammatory diseases: The Eurofever experience. Ann Rheum Dis 2012 Feb 29 (Epub ahead of print).

24. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: Evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006; 18: 108-17.

25. Gattorno M, Sormani P, D’Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 55: 1823-32.

26. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of Interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36.

27. Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor associated periodic syndrome (TRAPS): Clinical and laboratory findings in a series of seven patients. Rheumatology 2003; 42: 235-39.

28. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of Anakinra in patients with Tumor Necrosis Factor Receptor-Associated Perdiodic Syndrome. Arthritis Rheum 2008; 58: 1516-20.

29. Church LD, Churchman SM, Hawkins PN, et al. Hereditary autoinflammatory disorders and biologics. Springer Semin Immun 2006; 27: 494-508.

30. Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with Etanercept in two patients with the Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Arthritis Rheum 2003; 48: 2645-51.

31. Hoffman HM, Rosengren S, Boyle D, et al. Prevention of coldassociated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-85.

32. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal- Onset Multisystem Inflammatory Disease response to Interleukin- 1β inhibition. N Engl J Med 2006; 355: 581-92.

33. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features on Muckle-Wells syndrome and response to Anakinra. Arthritis Rheum 2004; 50: 607-12.

34. Dhimolea E. Canakinumab. mAbs 2010; 2: 3-13.

35. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of Rilonacept (Interleukin-1 Trap) in patients with Cryopyrin- Associated periodic syndromes. Arthritis Rheum 2008; 58: 2443-52.

36. Lukens JR, Dixit VD, Kanneganti TD. Inflammasome activation in obesity-related inflammatory diseases and autoimmunity. Discov Med 2011; 12: 65-74.